Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Recurrence 6Hodgkin Disease 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Leukemia 3Hematologic Neoplasms 3Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Anemia, Refractory, with Excess of Blasts 2Transplant-Related Hematologic Malignancy 1Teratoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

PM 01183 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pasireotide 1fludarabine phosphate 1fludarabine 1Zoledronic Acid 1Vincristine 1Temozolomide 1Mesna 1Irinotecan 1Injections 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Desmoplastic Small Round Cell Tumor × Granulocyte Colony-Stimulating Factor × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡